'None of this would be possible without the exceptional commitment of our people': Northern Ireland pharma leader reports record year with revenue topping £1.1bn
Craigavon’s Almac reports £71.9m revenue growth, 16% profit rise and workforce expansion to more than 7,900 as long-term investment continues to fuel global expansion
Northren Ireland-based Almac Group, the global contract pharmaceutical development and manufacturing organisation, has reported record financial results for the year ended September 30 2025, with revenue, profit and employment all reaching their highest levels in the company’s history.


Annual accounts released today (Tuesday) show revenue rose to £1.1 billion, an increase of £71.9 million (7%) compared with the previous year, reflecting continued demand across its global pharmaceutical and biotech client base.
Pre-tax profit increased by 16% to £138.9 million, up from £119.3 million in 2024, while employee numbers grew by 6% over the same period, reinforcing the organisation’s sustained expansion across international operations.
The Almac Group is a privately owned, globally recognised contract development and manufacturing organisation (CDMO), providing integrated services across the full drug development lifecycle. Its capabilities span research and development, biomarker discovery, API manufacture, analytical services, formulation development, clinical trial supply, interactive response technology (IRT/IVRS/IWRS), and commercial-scale manufacturing and distribution.
Headquartered in Craigavon, the Group has grown organically and now employs more than 7,900 highly skilled staff across 18 facilities in Europe, the United States and Asia. The financial figures relate to the period from 1 October 2024 to 30 September 2025.
Almac confirmed it continues to reinvest all profits back into the business to support long-term growth and capability expansion. The latest results mark the fifth year of its £500 million-plus global capital investment programme, first announced in November 2021.
Since the programme began, the Group has expanded its workforce by more than 2,000 employees, with over half of those roles created in Northern Ireland. Investment has been directed across multiple areas, including pharmaceutical and diagnostic development, clinical production and distribution, commercial manufacturing and packaging, global cold-chain infrastructure, analytical services, and major campus enhancements designed to improve working environments and operational capacity.
The Group said it continues to play a central role in the global development and supply of medicines, supporting the production and distribution of hundreds of treatments during the financial year across more than 20 therapeutic areas. These include oncology, cardiology, immunology, neurology and gene therapy, alongside other advanced and specialist treatment areas.
Alan Armstrong, chairman and chief executive of Almac Group, said the results demonstrated the strength and resilience of the company’s long-term strategy in a changing global environment.
“These results reflect another successful year for Almac and demonstrate the resilience of our long-term growth strategy in a changing global environment,” he said.
“As a privately owned company, we are proud to reinvest our profits to support our global clients, drive innovation and expand our capabilities. None of this would be possible without the exceptional commitment of our people across the globe.”
The Group added that continued investment in infrastructure and talent would remain central to its strategy as it looks to further expand capacity and strengthen its position as a leading global CDMO.
